(-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells

miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis

(2015)   Oncotarget

Down-Regulation of miR-101 in Endothelial Cells Promotes Blood Vessel Formation through Reduced Repression of EZH2

(2011) Michiel Smits et al.   PLoS One

Phosphorylation of the chromodomain changes the binding specificity of Cbx2 for methylated histone H3

(2010) Atsushi Hatano et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Regulation of the Polycomb protein RING1B ubiquitination by USP7

(2010) Prim de Bie et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

HDAC inhibitors repress the polycomb protein BMI1

(2010) Steven Grant   CELL CYCLE

The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors

(2010) Prashant V. Bommi et al.   CELL CYCLE

HDAC inhibitors conquer polycomb proteins

(2010) Paul Yaswen   CELL CYCLE

Histone deacetylase controls adult stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3

(2010) Ji-Won Jung et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines

(2010) Stefan Nagel et al.   Molecular Cancer

The epigenome as a therapeutic target in prostate cancer

(2010) Antoinette S. Perry et al.   Nature Reviews Urology

Nucleoside Drugs Induce Cellular Differentiation by Caspase-Dependent Degradation of Stem Cell Factors

(2010) Tanja Musch et al.   PLoS One

Polycomb Target Genes Are Silenced in Multiple Myeloma

(2010) Antonia Kalushkova et al.   PLoS One

Epigenetic Analysis of KSHV Latent and Lytic Genomes

(2010) Zsolt Toth et al.   PLoS Pathogens

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

(2009) W. Fiskus et al.   BLOOD

Epigallocatechin-3-Gallate, a Histone Acetyltransferase Inhibitor, Inhibits EBV-Induced B Lymphocyte Transformation via Suppression of RelA Acetylation

(2009) K.-C. Choi et al.   CANCER RESEARCH

EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance

(2009) M.-L. Suva et al.   CANCER RESEARCH

Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma

(2009) Junpei Yamaguchi et al.   CANCER SCIENCE

The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival

(2009) S. Balasubramanian et al.   CARCINOGENESIS

In Brief

(2009)   NATURE REVIEWS NEUROSCIENCE

Effect of genistein on the bioavailability and intestinal cancer chemopreventive activity of (-)-epigallocatechin-3-gallate

(2008) J. D. Lambert et al.   CARCINOGENESIS

Ezh2 Requires PHF1 To Efficiently Catalyze H3 Lysine 27 Trimethylation In Vivo

(2008) K. Sarma et al.   MOLECULAR AND CELLULAR BIOLOGY

Roles of the EZH2 histone methyltransferase in cancer epigenetics

(2008) Jeffrey A. Simon et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

The Bmi-1 polycomb group gene in skin cancer: regulation of function by (−)-epigallocatechin-3-gallate

(2008) Sivaprakasam Balasubramanian et al.   NUTRITION REVIEWS

Expression of Bmi-1 in Epidermis Enhances Cell Survival by Altering Cell Cycle Regulatory Protein Expression and Inhibiting Apoptosis

(2007) Kathy Lee et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY